Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study was to investigate the effects of etomidate or sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery profiles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sevoflurane in Electroconvulsive Therapy

NCT01905904

ECT Anesthesia

COMPLETED PHASE4

Three Anaesthesic Method in Electroconvulsive Theraphy

NCT01759589

Anesthesia

COMPLETED PHASE4

Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy

NCT02267980

Depressive Disorder

UNKNOWN PHASE4

Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy

NCT01870219

Major Depression Electroconvulsive Therapy

COMPLETED PHASE4

The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy

NCT02271555

Haemodynamic Rebound

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Twenty-five patients will be a total of 150 ECT treatments in this prospective, double-blinded, crossover study. Each patient will receive either 0.2 mg/kg etomidate (Group 1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of consciousness for their initial electroconvulsive therapy session. In subsequent sessions, patients will receive the alternative sevoflurane concentration and then alternated between doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine. Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean arterial pressure (MAP) values, and recovery times will recorde.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia ECT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Etomidate

0.2 mg/kg etomidate during anesthesia induction

Group Type ACTIVE_COMPARATOR

Etomidate

Intervention Type DRUG

0.2 mg/kg etomidate

Sevoflurane

Intervention Type DRUG

8% Sevoflurane

8% sevoflurane

Sevoflurane 8% concentration during anesthesia induction

Group Type ACTIVE_COMPARATOR

Etomidate

Intervention Type DRUG

0.2 mg/kg etomidate

Sevoflurane

Intervention Type DRUG

8% Sevoflurane

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etomidate

0.2 mg/kg etomidate

Intervention Type DRUG

Sevoflurane

8% Sevoflurane

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hypnomidate Sevorane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Study include 25 patients of American Society of Anesthesiologists (ASA) physical status I-II aged between 18-60 years who schedule for ECT sessions under general anesthesia

Exclusion Criteria

* Pregnancy
* Cerebrovascular disease
* Epilepsy
* Unstable cardiovascular disease
* Chronic obstructive pulmonary disease; and
* Renal or hepatic failure

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No